Recursion Pharmaceuticals (RXRX) Other Operating Expenses (2022 - 2026)

Recursion Pharmaceuticals has reported Other Operating Expenses for 5 years, with the latest figure at $12.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 42.78% year-over-year to $12.5 million; the trailing twelve-month figure through Mar 2026 stood at $61.6 million (up 10.22% YoY), and the FY2025 full-year result was $71.0 million, up 56.84% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $12.5 million, down from $14.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $21.8 million in Q1 2025, with the low at $7.8 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $12.9 million across 5 years, with a median of $12.4 million in 2023.
• Annual changes were most pronounced in 2025 — Other Operating Expenses jumped 119.17% — and 2026, when it slumped 42.78%.
• Recursion Pharmaceuticals' Other Operating Expenses stood at $10.8 million in 2022, then fell by 8.85% to $9.9 million in 2023, then climbed by 29.48% to $12.8 million in 2024, then increased by 11.58% to $14.3 million in 2025, then fell by 12.5% to $12.5 million in 2026.
• The last three Other Operating Expenses figures came in at $12.5 million (Q1 2026), $14.3 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.